BioXcel Therapeutics posted a net loss of $30.9 million in Q3 2025, reflecting higher R&D costs tied to late-stage clinical trials and reduced revenue from IGALMI®. Operating losses narrowed slightly year-over-year as SG&A costs declined due to prior restructuring.

BioXcel Therapeutics posted Q2 2025 revenue of $120,000 from IGALMI, down from $1.1 million YoY, reflecting minimal commercial activity. Net loss widened to $19.2 million, mainly due to increased R&D for the SERENITY at-home Phase 3 trial and higher interest expense. However, SG&A expenses declined due to reprioritization efforts. The company ended the quarter with $18.6 million in cash.

BioXcel Therapeutics reported a net loss of $7.3 million for the first quarter of 2025, a significant improvement from the $26.8 million net loss in the same period of 2024. Revenue from IGALMI® decreased to $168,000 from $582,000 year-over-year. The company also announced the full enrollment of its SERENITY At-Home pivotal Phase 3 safety trial, with topline data expected in the second half of 2025.

In Q4 2024, BioXcel Therapeutics posted $366,000 in revenue from IGALMI, with a net loss of $10.86 million or -$3.57 per share. Both R&D and SG&A expenses were significantly reduced compared to the prior year, contributing to a narrower operating loss. The company ended the quarter with $29.85 million in cash and continues to focus on advancing the SERENITY and TRANQUILITY programs.

BioXcel Therapeutics reported a net revenue of $214 thousand for the third quarter of 2024, a decrease compared to $341 thousand for the same period in 2023. R&D expenses decreased to $5.1 million, and SG&A expenses decreased to $7.7 million. The company's net loss was $13.7 million, compared to a net loss of $50.5 million for the same period in 2023. Cash and cash equivalents totaled $40.4 million as of September 30, 2024.

BioXcel Therapeutics reported a net revenue of $1.1 million from IGALMI, a 141% increase compared to the same period in 2023. The company's net loss was $8.3 million, significantly lower than the $53.5 million loss in the second quarter of 2023. The company used $23.2 million in operating cash during the second quarter of 2024, and cash and cash equivalents totaled $56.3 million as of June 30, 2024.

BioXcel Therapeutics reported its Q1 2024 financial results, highlighting a 182% increase in IGALMI net revenue compared to the same period last year, driven by increasing demand and new customer orders. The company is advancing its TRANQUILITY and SERENITY programs and strengthened its balance sheet with a $25 million registered direct offering.

BioXcel Therapeutics reported Q4 2023 financial results, including net revenue from IGALMI of $376,000, R&D expenses of $9.9 million, SG&A expenses of $9.6 million, and a net loss of $22.3 million. The company is focusing on advancing its TRANQUILITY and SERENITY clinical programs.

BioXcel Therapeutics reported a net revenue of $341,000 for IGALMI in Q3 2023. The company's R&D expenses were $19.6 million, and SG&A expenses were $24.3 million. The net loss for the quarter was $50.5 million. Cash and cash equivalents totaled $90.0 million as of September 30, 2023.

BioXcel Therapeutics reported Q2 2023 financial results, highlighting a strategic reprioritization to focus on high-potential agitation market opportunities and reduce operating expenses. The company is shifting its commercial strategy for IGALMI and reducing its workforce to extend its cash runway through mid-2024.

BioXcel Therapeutics reported a net revenue of approximately $206,000 for the quarter. The company's net loss was $52.8 million. Cash and cash equivalents totaled $165.5 million as of March 31, 2023.

BioXcel Therapeutics reported Q4 2022 financial results with a net revenue of $238,000 and a net loss of $54.8 million. The company is focused on the commercial execution of IGALMI and anticipates pivotal data readouts for BXCL501 in Q2 2023.

BioXcel Therapeutics reported net revenue of $137,000 for the third quarter of 2022. The company's net loss was $41.8 million, and cash and cash equivalents totaled approximately $232.3 million as of September 30, 2022.

BioXcel Therapeutics reported a net loss of $37.7 million for the second quarter of 2022. As of June 30, 2022, cash and cash equivalents totaled approximately $233.5 million. The company commercially launched IGALMI™ and is advancing its clinical pipeline.

BioXcel Therapeutics reported a net loss of $31.5 million for the first quarter of 2022. The company received FDA approval for IGALMI and extended its cash runway into 2025 with a $260 million strategic financing.

BioXcel Therapeutics reported a net loss of $26.1 million for the fourth quarter of 2021, compared to a net loss of $21.1 million for the same period in 2020. As of December 31, 2021, cash and cash equivalents totaled approximately $233.0 million.

BioXcel Therapeutics reported a net loss of $26.8 million for the third quarter of 2021, with cash and cash equivalents totaling approximately $252.9 million as of September 30, 2021. The company is progressing with commercial and launch readiness for BXCL501 and advancing its neuroscience and immuno-oncology franchises.

BioXcel Therapeutics reported a net loss of $27.6 million for the second quarter of 2021. As of June 30, 2021, cash and cash equivalents totaled approximately $273.1 million.

BioXcel Therapeutics reported a net loss of $26.4 million for the first quarter of 2021. As of March 31, 2021, cash and cash equivalents totaled approximately $194 million. The company received Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia and submitted NDA to FDA for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders.

BioXcel Therapeutics reported a net loss of $21.1 million for the fourth quarter of 2020, compared to a net loss of $8.3 million for the same period in 2019. As of December 31, 2020, cash and cash equivalents totaled approximately $213.1 million.

BioXcel Therapeutics reported a net loss of $24.8 million for the third quarter of 2020. The company's NDA submission for BXCL501 is on track for Q1 2021, and clinical trials for BXCL501 and BXCL701 are progressing. The company's cash position remains strong at $233.4 million.

BioXcel Therapeutics reported positive results from its SERENITY trials for BXCL501, plans to submit an NDA to the FDA in Q1 2021, and strengthened its balance sheet through a follow-on offering. The company is also advancing its TRANQUILITY and RELEASE trials and exploring alternative indications for BXCL501. Additionally, the immuno-oncology program is progressing with the Phase 2 efficacy trial of BXCL701 and KEYTRUDA®.

BioXcel Therapeutics reported a net loss of $14.9 million for the first quarter of 2020. The company highlighted progress in its clinical trials for BXCL501 and BXCL701 and strengthened its balance sheet through a follow-on offering, raising approximately $60 million in net proceeds.

BioXcel Therapeutics reported a net loss of $8.3 million for the fourth quarter of 2019, compared to a net loss of $7.1 million for the same period in 2018. Research and development expenses were $6.5 million, and general and administrative expenses were $1.9 million.